• While analysing past data, we can use this formula :
- Sales Growth (5 years) > 15%
- RoCE > 15% or RoE > 12%
- Net Debt/Equity < 0.1
(6/n)
• Estimating forward valuations : This is a very tricky part of selecting the stocks.
• Based on recent quarterly earnings and management's guidance, you will have to project the future earnings.
• In this case, sectorial tailwinds must be in favour of the company.
(7/n)
• While forecasting the valuations, please keep a note on :
- OPM in improving trend (last few quarters)
- Avoid capital intensive sectors (such as metal)
- Management guidance and their execution
- Sectorial tailwinds in favour
(8/n)
(iii) How to review and decide :
• Check the quarterly earnings and attend con-calls.
• Review their Half-Yearly and Yearly results where company posts balance sheet along with CFO statement.
• Compare the guidance given with what they delivered.
(9/n)
• While checking B/S or CFO statement, Do check :
- Trade Receivables - Significant increase - Negative
- Cash + Investment Value - Increase - Positive
- OCF conversion from EBITDA - High - Positive
- Working capital cycle & management
(10/n)
- Higher CWIP - Capex - Positive in longer run
- Contingent liabilities - High - Negative
- Net fixed asset turnover (NFAT)
- RoIC and RoCE.
• Invest in the businesses which can generate higher RoCE and OCF from their businesses.
(11/n)
(iv) Perfect time to exit / pyramiding :
"Always remember : When everyone is greedy, be fearful and when everyone is fearful, be greedy."
Track the business, valuation metrics & decide.
I hope this thread will add some value to your analysis.
Thanks for reading😊
(12/12)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
The company has done fairly well & will be expanding its module mfg capacities from 450 MW to 1.2 GW & backward integrating by doing capex in Al-Frame.
🧵A Thread 🧵
The company has 17+ years of experience in solar PV mfg industry.
Current capacity is 450MW - most of the sales are derived from domestic markets.
Alpex is led by promoters with cumulative experience of 80+ years.
Aditya Sehgal (2nd generation) is director (global sales).
6 Dossiers filed for OTF, 5 MA were received on dossiers.
5.3 Cr (8% of operating revenue) was spent on R&D.
Capex of 18.1 Cr during Q1 on new warehouse, manufacturing facilities etc.
Operational Updates :
- Marketing partnership in AU & NZ markets.
- Successful Audit by NSF.
- Received 30.6 Cr (Gross) from Escrow account sale - to be deployed for Debt Reduction & Investments.
- Focusing on MENA region through partners.
FY23 PAT 13.25 Cr on 48.76 Cr Sales ~ 27% Net Margin👌
FY23 EBITDA 19.33 Cr ~ 39.6% Operating Margins
Trading at 17x EV/EBITDA & 24.6x FY23 EPS
D - No reco. ; studying about it currently
Balance Sheet :
Debt reduction : 19.3 Cr in FY22 to 4 Cr in FY23
Net-worth has increased from 18.6 Cr to 41.2 Cr
Fixed asset addition of 3 Cr during FY23 ; CWIP of 7.52 Cr
Cash Flows :
Net cash flow from operations at 16.29 Cr
Capex of 9.85 Cr during FY23 ~ FCF of 6.44 Cr
Debt repayment of 15.34 Cr during FY23
A very under-researched but very impressive Small Cap Pharma Company
R&D spend : 26Cr (FY23) ; 84 Cr in last 4 years
PAT : 24 Cr (FY23) ; 49 Cr in last 4 years (cumulative)
🧵A Thread 🧵
Current business : 77% from Pharma & 23% from Nutraceuticals
NIP (New Innovative Products) : 2 products filed in the EU; 8 products under development for developed markets; 4 developed market filings planned in FY24
- 10 NIPs in various stages of development
- Rs 62 Cr invested in gross block over last 4 years
- 44 products received registration during FY23
- 5 Marketing Authorisations received on ZIM’s Dossiers in EU in FY23